The GIFT Nifty futures, which are an early indicator of the Nifty50 index stocks, were trading lower by 54 points at 25,465, indicating that the domestic benchmark indices are likely to make a negative start on Monday. 

Earlier on Friday, 13 February, the domestic benchmark indices S&P BSE Sensex crashed by 1,048.16 points or 1.25%, and settled at 82,626, while the Nifty50 traded 1.30% lower or 336 points, closing at 25,471.

Here are some stocks that are likely to remain in focus on 16 February.

Garden Reach Shipbuilders: State-run defence company Garden Reach Shipbuilders & Engineers has commenced construction of two Coastal Research Vessels for the Geological Survey of India. The company marked the start of the project with a steel-cutting ceremony attended by officials from both organisations. These vessels will strengthen India’s coastal research capabilities and support various marine and geological studies.

Hindustan Copper: The Government of Jharkhand has issued a demand notice seeking Rs 929.4 crore from Hindustan Copper, alleging that the company carried out production at the Surda mine without valid statutory clearances or beyond permissible limits between FY2000-01 and FY2016-17.

Religare Enterprises: The boards of Religare Enterprises and Religare Finvest have approved a demerger to separate the financial services and insurance businesses into two independently listed entities. Under the scheme, Religare Finvest will issue fully paid-up equity shares to Religare Enterprises shareholders in a 1:1 ratio. After the demerger, Religare Finvest’s shareholding structure will mirror Religare Enterprises’ pre-demerger pattern.

Lodha Developers: Lodha Developers has signed a Share Purchase Agreement to acquire an 80% stake in Solidrise Realty (SRPL) for Rs 294 crore. Upon completion, SRPL, which operates in Pune’s real estate market, will become a subsidiary of the company.

Natco Pharma: Natco Pharma has obtained approval from the Central Drugs Standard Control Organisation (CDSCO) to manufacture and market generic Semaglutide injection in India. The company plans to launch the product in March 2026. Doctors prescribe Semaglutide to treat adults with inadequately controlled type 2 diabetes alongside diet and exercise.

Zydus Lifesciences: Zydus Lifesciences has received final US FDA approval for Ammonium Lactate Cream, 12%. The topical prescription medication treats dry, scaly skin (xerosis) and ichthyosis vulgaris by improving hydration, reducing itching, softening the skin, and minimising scaling.

Deep Industries: Deep Industries has secured a Letter of Award from Oil India for hiring a 1,000 HP mobile drilling rig package in Assam and Arunachal Pradesh. The contract carries an estimated value of approximately Rs 148 crore.

Ashoka Buildcon: Ashoka Buildcon has received a Letter of Acceptance from Liberia’s Ministry of Public Works for a $45.27 million infrastructure project. The project involves upgrading multiple road stretches, including the Nrowkia (Sasstown Junction) to Barclayville route, in the Republic of Liberia.

Aurobindo Pharma: Aurobindo Pharma’s subsidiary, Acrotech Biopharma Inc., has received US FDA approval for the New Drug Application (NDA) for ADQUEY (difamilast 1%) ointment. The drug treats mild-to-moderate atopic dermatitis in adults and children aged two years and above.

Jubilant Pharmova: Jubilant HollisterStier General Partnership (JHSGP) announced that the US FDA classified its Montreal contract manufacturing facility as Official Action Indicated (OAI) following inspections conducted in October and November 2025.

Alkem Laboratories: The US FDA completed a pre-approval inspection at Enzene Biosciences, a subsidiary of Alkem Laboratories, and issued a Form 483 with six procedural observations. Enzene reported zero data integrity observations, reinforcing the strength of its quality systems and regulatory processes.

Discover the next big investment! Tradz by EquityPandits’ IPO screener helps you identify promising initial public offerings. Download Tradz by EquityPandit and get ahead of the curve! Sign Up Now & Find Your Next IPO Gem!